Fmoc-D-valine (C₂₀H₂₁NO₄, 339.39 g/mol) is received as a crystalline solid and used as a protected chiral building block in solid-phase peptide synthesis (SPPS). The material is dissolved in anhydrous DMF at 0.10–0.30 M before automated coupling. In a C-terminal peptide acid route, Fmoc-D-valine is anchored to 2-chlorotrityl chloride resin with substitution 0.8–1.5 mmol/g in anhydrous dichloromethane using 4 equiv DIPEA relative to resin loading. The anchor reaction proceeds at 20–25°C for 60 min, and unreacted chloride sites are capped with methanol for 15 min. Fmoc removal is performed with 20% v/v piperidine in DMF using two 5 min treatments followed by a 15 min treatment. The piperidine effluent is monitored at 301 nm to quantify the dibenzofulvene adduct. When Fmoc-D-valine is introduced as an incoming amino acid above a resin-bound amine, coupling is completed with HBTU/HOBt/DIPEA at 4 equiv amino acid, 4 equiv HBTU, 4 equiv HOBt, and 8 equiv DIPEA in DMF. A 30 min room-temperature coupling is followed by a Kaiser test; a second coupling is applied when resin beads remain blue. This double-coupling sequence addresses the β-branched steric hindrance of valine and avoids incomplete chain extension in D-Val-containing therapeutic peptide acids.

Following linear assembly, the peptide is cleaved from 2-chlorotrityl resin with TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v) at 20°C for 2 h. The filtrate is concentrated and precipitated in cold methyl tert-butyl ether; the precipitate is lyophilized to a white powder. Preparative reverse-phase HPLC on a C18 column with 0.1% TFA water/acetonitrile gradient provides the final peptide acid. In GMP peptide API production, Fmoc-D-valine is received under ICH Q7 starting-material controls; analytical release includes HPLC area normalization ≥98.0% by USP <621>, residual solvent testing under ICH Q3C, and enantiomeric purity by chiral HPLC. Residual L-valine is treated as a critical impurity because D/L inversion produces a diastereomeric peptide that co-purifies with the target and may alter pharmacological activity. D-Val-containing peptide acids are then formulated as acetate or trifluoroacetate salts for downstream lyophilized drug product.

Why Does Microwave-Assisted Fmoc-D-Valine Coupling Require Racemization Monitoring at 50–60°C?

Microwave-assisted SPPS accelerates Fmoc-D-valine coupling on β-branched sequences, but the same thermal input can promote oxazolone formation and D-to-L inversion. Automated synthesizers such as the CEM Liberty Blue or Biotage Alstra use fiber-optic temperature feedback in PTFE reaction vessels; a standard Fmoc-D-valine cycle uses 3 equiv Fmoc-D-valine, 3 equiv DIC, and 3 equiv Oxyma in DMF at 50°C for 10 min, followed by a second coupling at 60°C for 10 min. Deprotection uses 20% v/v piperidine/DMF at 90°C for 60 s followed by a second 3 min treatment. The primary process conflict is that D-Val is β-branched; conventional room-temperature coupling with DIC/HOBt can leave residual free amine, yet excessive microwave cycling raises the risk of configurational erosion. Therefore, the crude linear peptide is analyzed by LC-MS after a stepwise miniature cleavage. Diastereomeric peptide by-products containing L-valine are separated on a C18 column at 40°C with 0.1% formic acid in water/acetonitrile; detection is at 214 nm. The acceptance threshold for the L-Val diastereomer is typically ≤0.5% by UV area. Where coupling yields are incomplete, a third 5 min coupling with 2 equiv Fmoc-D-valine and DIC/Oxyma is inserted before capping.

Resin-bound reaction progress is monitored with the bromophenol blue test for secondary amines; a colorless or pale-yellow bead state indicates completion, while persistent blue signals require extension of the coupling cycle. Because Fmoc-D-valine has a free acid group, its dissolution in DMF must be complete prior to activation; turbid solutions can produce variable equivalents and lower coupling repeatability. The product is typically advanced without isolation of the protected intermediate. For APIs intended for human use, the diastereomer is controlled in the final peptide by ICH Q6B specification; if the L-Val impurity cannot be removed by preparative HPLC, the microwave cycle is replaced with 20°C HATU/HOAt double coupling. This fallback reduces throughput but preserves enantiopurity.

Rheological Failure Envelope of Fmoc-D-Valine-Capped Peptide Gelators

Short Fmoc-capped peptides containing D-valine are prepared as candidate low-molecular-weight gelators for injectable depot research. The Fmoc-D-valine residue is introduced at the N-terminus of a dipeptide or tripeptide via standard Fmoc-SPPS on a 2-chlorotrityl chloride resin. The crude peptide is purified by RP-HPLC and lyophilized; gelation is triggered by pH adjustment, solvent switch from DMSO to water, or thermal annealing at 80°C followed by cooling to 25°C. Oscillatory rheology is performed on an Anton Paar MCR 302 with a 40 mm parallel-plate geometry and a 1 mm gap. An amplitude sweep at 1 Hz identifies the linear viscoelastic region; a subsequent frequency sweep from 0.1 Hz to 10 Hz at 0.1% strain records storage modulus G′ and loss modulus G″. A gel is defined operationally as G′ exceeding G″ at 5 Hz. Published data for the D-valine configuration in this exact Fmoc-capped peptide gelator class is limited, and the absolute rheological values depend on the paired L-amino acid, terminal charge, and ionic strength. D-valine may invert the supramolecular chirality observed by circular dichroism without necessarily raising gel stiffness. The process window is narrow: gelation can be suppressed below 0.5 wt% peptide and can phase-separate above 2.0 wt% depending on sequence. Syringeability through a 27 G needle is assessed by extrusion force; gels with yield stress above 200 Pa may require larger-gauge administration needles.

The terminal use is generally confined to non-implantable or laboratory models because the fluorenylmethoxycarbonyl group is not a pharmaceutically cleared fragment for parenteral depots. Cytocompatibility is assessed with ISO 10993-5 elution assays on L929 fibroblasts; leachables data are generated by LC-MS and total organic carbon, with acceptance limits defined by the intended route of administration. Fmoc-D-valine-containing gelators are therefore screened in vitro rather than directly progressed into GMP medical device manufacturing. Batch-to-batch variability in gel stiffness is minimized by lyophilized peptide storage at −20°C under argon, because Fmoc group hydrolysis at ambient humidity can reduce gelator solubility.

Split-and-pool peptide library production uses Fmoc-D-valine as a chirally defined diversification monomer. The resin is typically TentaGel S RAM with a Rink amide linker at 0.2–0.3 mmol/g. Fmoc deprotection is carried out with 20% v/v piperidine/DMF for 20 min, and the resin is washed with DMF, dichloromethane, and methanol. For each coupling position, the resin is split into reaction vessels; Fmoc-D-valine is activated with PyBOP/HOBt/DIPEA at 4 equiv Fmoc-D-valine, 4 equiv PyBOP, 4 equiv HOBt, and 8 equiv DIPEA in NMP at 20–25°C for 30 min. A second 30 min coupling is used because β-branched valine on library resin often shows incomplete acylation. Unreacted amines are capped with acetic anhydride/pyridine (1:1 v/v) for 10 min. After washing, resin-bound peptides are cleaved with TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v) for 3 h. The peptide libraries are precipitated in cold methyl tert-butyl ether, reconstituted in 50% acetonitrile/water, and lyophilized. Analytical validation uses LC-MS with a C18 column, 0.1% formic acid modifier, and a 5–60% acetonitrile gradient over 20 min; MALDI-TOF mass spectra confirm peptide identity. D-valine incorporation is confirmed by MS/MS fragmentation and, where required, by acid hydrolysis and chiral amino acid analysis. These libraries are terminal research reagents for epitope mapping, enzyme substrate determination, and on-bead screening. The D-valine residue is selected to increase chemical diversity and to probe chiral recognition by the target receptor; it is not a GMP drug substance.

When Fmoc-D-Valine Is Introduced as a Degradation-Resistant Substitution in Peptide Amides

Fmoc-D-valine is used during SPPS to insert a D-amino acid at a peptide amide position that otherwise undergoes serine protease cleavage. The final peptide is assembled on Rink amide MBHA resin at 0.4–0.6 mmol/g; Fmoc-D-valine is coupled with HATU/HOAt/DIPEA at 4 equiv, 4 equiv, and 8 equiv in DMF for 25 min at 20°C. Double coupling is applied routinely. After TFA cleavage and RP-HPLC purification, the peptide amide is subjected to in vitro plasma stability testing in EDTA-anticoagulated human plasma at 37°C, with sampling at 0 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, and 24 h. Samples are precipitated with acetonitrile containing 0.1% formic acid; the supernatant is analyzed by LC-MS/MS using multiple reaction monitoring. The D-Val substitution can extend the terminal half-life, but published data for this specific configuration is limited; the magnitude of stabilization is sequence-dependent and must be verified against the L-Val counterpart in the same assay. Loss of target potency is assessed separately by receptor binding or enzymatic activity assays.

The critical operational boundary is that D-Val substitution does not universally improve plasma stability and may reduce manufacturing yield because β-branching slows coupling. If the final peptide exhibits low solubility in aqueous buffer at pH 7.4, formulation requires pH adjustment or a lyophilized acetate salt. Peptide amides containing D-Val are stored at −20°C in glass vials under nitrogen; repeated freeze-thaw cycles above 5 cycles can promote aggregation. In GMP manufacturing, the starting Fmoc-D-valine must have controlled residual solvents according to ICH Q3C and a certificate of analysis demonstrating HPLC purity ≥98.0%, water content ≤1.0%, and enantiomeric purity by chiral HPLC. Process development may evaluate a switch from Fmoc-D-valine to Boc-D-valine only for N-terminal positions where Fmoc deprotection with piperidine would expose an incompatible side-chain protecting group.